Grail Inc (GRAL) Stock Price, Quote & News

Company Profile

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therap...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 833 694 2553

Website: grail.com

Address:

1525 O’Brien Drive, Menlo Park, United States

BinaryLogic Jun. 23 at 1:03 AM

$GRAL just made news on NPR for its Galleri test pending FDA approval at the close of the year. GRAL has a market cap of $2.7B. While the Galleri test is pioneering liquid biopsy technology, it is relatively expensive $1000, long-lead and limited to specialized technical labs. Contrast that with $VNRX CaptureSeq which shows comparable specificity, but outstanding detection of Phs-1/2 cancers at a fraction of the cost using technology at nearly any/all hospitals worldwide. IP secured to 2044 and market cap of $12M, grossly Oversold and in discussions with all leading liquidity biopsy/diagnostic Companies globally on licensing agreements. https://www.npr.org/2026/06/21/nx-s1-5858691/blood-test-multi-cancer-early-detection-mced

1 · Reply

bonniewinter Jun. 16 at 5:35 PM

$GRAL looks like Goldman Sachs $60PT has places a lid on the share price. Grails’s MCED test Galleri is being adopted well with private payors and Tricare. Revenue is exceeding expectations each quarter. All clinical trials including Pathfinder 2 and UK NHS trial have confirmed superior clincial validity which is the main basis for FDA approval. Regarding clinical utility, they showed a remarkable 20% improvement in delaying progression to Stage 4 cancers and have commenced the REACH trial with Medicare patients to confirm this finding from the UK trial. The Medical Oncology community and cancer patients are elated about early detection and early interventions for many cancers which still do not have any primary screening. Bill Gates & Jeff Bezos remain large shareholders of this industry disruptor technology, the first of its kind which will achieve FDA APPROVAL soon.

0 · Reply

Bazzzigar Jun. 9 at 5:40 PM

$GRAL moved to MANE

0 · Reply

TheUnmaker Jun. 9 at 11:47 AM

$TNXP $GRAL $CCCC $QSI

0 · Reply

ripster47 Jun. 5 at 3:12 PM

$GRAL | Goldman Sachs Starts GRAIL, Inc. PT to $60 on Regulatory Milestones Goldman Sachs initiates coverage as FDA approval, CMS coverage, and MCED adoption remain key growth determinants 🔹 Follow @tenet_research for more analyst insights on other tickers.

0 · Reply

LewisDaKat Jun. 5 at 10:30 AM

$GRAL GRAL Price Target Alert: $60.00. Issued by Goldman Sachs https://marketwirenews.com/stock/gral/news/gral-price-target-alert-60-00-issued-by-goldman-sach-7221385765324160.html?utm_source=stocktwits

0 · Reply

LewisDaKat Jun. 5 at 10:00 AM

$GRAL Neutral Recommendation Issued On GRAL By Goldman Sachs https://marketwirenews.com/stock/gral/news/neutral-recommendation-issued-on-gral-by-goldman-sac-6688585928039035.html?utm_source=stocktwits

0 · Reply

gobio Jun. 5 at 12:14 AM

$GRAL https://www.statnews.com/2026/06/04/grail-multi-cancer-early-detection-test-trial-results/?utm_campaign=daily_recap&utm_medium=email&_hsenc=p2ANqtz-9ialr9z14UWDBeQ8mfefa1-B9rldpk8RJlOBPw4bFeO1wzj9_XIlVsit_cYS7grXgyiESn2M_IvnEBocosqAh9eq4knw&_hsmi=422308760&utm_content=422308760&utm_source=hs_email

0 · Reply

LewisDaKat Jun. 4 at 8:00 PM

$GRAL Why Grail Stock Popped Today https://marketwirenews.com/stock/gral/news/why-grail-stock-popped-today-4936013861703078.html?utm_source=stocktwits

0 · Reply

LewisDaKat Jun. 4 at 7:30 PM

$GRAL Is Grail Stock a Bad-News Buy After Its Recent Pullback? https://marketwirenews.com/stock/gral/news/is-grail-stock-a-bad-news-buy-after-its-recent-pullb-8995358004223520.html?utm_source=stocktwits

0 · Reply

GRAIL, Inc. (GRAL) Securities Fraud: Contact Berger Montague to Discuss Your Rights

Jul 1, 2026, 6:21 PM EDT - 3 days ago

GRAL Investors Have Rights – If You Lost Money Investing in Grail, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Jun 25, 2026, 9:00 AM EDT - 9 days ago

GRAIL Completes $110 Million Equity Financing With Samsung Entities

Jun 18, 2026, 4:00 PM EDT - 16 days ago

GRAIL Transcript: AGM 2026

Jun 12, 2026, 4:07 PM EDT - 22 days ago

GRAL Breaking News: GRAIL, Inc. Sued for Securities Fraud after Trial Results Lead to 50% Stock Drop – Investors Notified to Contact BFA Law

Jun 11, 2026, 9:35 AM EDT - 23 days ago

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 4, 2026 in Grail, Inc. Lawsuit - GRAL

Jun 10, 2026, 9:47 AM EDT - 24 days ago

GRAIL, INC. (GRAL) INVESTOR ALERT Investors With Large Losses in GRAIL, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jun 9, 2026, 11:20 AM EDT - 25 days ago

GRAIL Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-05T08:40:29.000Z - 4 weeks ago

Grail initiated with a Neutral at Goldman Sachs

Jun 3, 2026, 7:35 AM EDT - 4 weeks ago

GRAIL Transcript: Jefferies Global Healthcare Conference 2026

2026-06-01T20:52:46.000Z - 4 weeks ago

Grail assumed with a Peer Perform at Wolfe Research

2026-06-01T16:35:00.000Z - 4 weeks ago

Grail falls -15.6%

2026-06-01T16:10:37.000Z - 4 weeks ago

Grail falls -18.4%

May 31, 2026, 7:00 PM EDT - 4 weeks ago

GRAIL Transcript: Study result

May 31, 2026, 7:00 PM EDT - 4 weeks ago

GRAIL Press release: Study result

May 31, 2026, 7:00 PM EDT - 4 weeks ago

GRAIL Slides: Study result

2026-05-31T21:43:31.000Z - 4 weeks ago

Grail presents ‘positive’ performance, safety results from Pathfinder 2 study

2026-05-31T21:36:48.000Z - 4 weeks ago

Grail reports results from NHS-Galleri trial in presentation at ASCO meeting

May 31, 2026, 8:00 AM EDT - 4 weeks ago

GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting

May 30, 2026, 8:00 AM EDT - 5 weeks ago

GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting

May 27, 2026, 4:01 PM EDT - 5 weeks ago

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 26, 2026, 4:01 PM EDT - 5 weeks ago

GRAIL to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 21, 2026, 4:01 PM EDT - 6 weeks ago

GRAIL to Present at the 2026 Jefferies Global Healthcare Conference

May 12, 2026, 11:40 AM EDT - 7 weeks ago

GRAIL Transcript: Bank of America Global Healthcare Conference 2026

2026-05-07T09:18:38.000Z - 2 months ago

Grail price target lowered to $70 from $82 at Baird

2026-05-07T07:52:29.000Z - 2 months ago

Grail price target raised to $56 from $54 at Piper Sandler

2026-05-07T05:21:56.000Z - 2 months ago

Grail price target raised to $69 from $65 at TD Cowen

May 6, 2026, 10:00 AM EDT - 2 months ago

Zaya Younan Unveils the Scientific Holy Grail of Cigar Smoking

2026-05-05T20:33:50.000Z - 2 months ago

Grail reports Q1 EPS ($2.29), consensus ($1.96)

May 5, 2026, 4:30 PM EDT - 2 months ago

GRAIL Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 2 months ago

GRAIL Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 2 months ago

GRAIL Quarterly report: Q1 2026

May 5, 2026, 4:01 PM EDT - 2 months ago

GRAIL Reports First Quarter 2026 Financial Results

Apr 30, 2026, 4:01 PM EDT - 2 months ago

GRAIL to Present at the BofA Securities 2026 Health Care Conference

Apr 28, 2026, 8:00 AM EDT - 2 months ago

GRAIL Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

GRAIL Proxy statement: Proxy filing

Apr 22, 2026, 4:01 PM EDT - 2 months ago

GRAIL to Announce First Quarter 2026 Financial Results

Apr 21, 2026, 4:53 PM EDT - 2 months ago

GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting

2026-04-10T09:55:12.000Z - 3 months ago

Grail initiated with a Neutral at Mizuho

2026-04-10T08:45:11.000Z - 3 months ago

Grail initiated with a Neutral at Piper Sandler

2026-04-07T20:05:13.000Z - 3 months ago

Grail announces collaboration with Epic to bring Galleri test to EHR platforms

Apr 7, 2026, 4:01 PM EDT - 3 months ago

GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide

2026-04-01T17:15:43.000Z - 3 months ago

Grail, Superpower partner to expand early cancer detection

Apr 1, 2026, 1:09 PM EDT - 3 months ago

Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection

2026-03-30T11:54:36.000Z - 3 months ago

Grail price target lowered to $75 from $130 at Guggenheim

2026-03-18T09:45:11.000Z - 3 months ago

Grail upgraded to Buy from Hold at TD Cowen

Mar 12, 2026, 6:13 PM EDT - 4 months ago

Grail CEO Bob Ragusa to retire, Josh Ofman named successor

2026-03-12T20:41:38.000Z - 4 months ago

Grail CEO Bob Ragusa retiring, Josh Ofman appointed successor

Mar 12, 2026, 4:30 PM EDT - 4 months ago

GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor

Mar 5, 2026, 9:00 AM EST - 4 months ago

Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed

Mar 3, 2026, 10:30 AM EST - 4 months ago

GRAIL Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 4:02 PM EST - 4 months ago

GRAIL to Present at the TD Cowen 46th Annual Health Care Conference

2026-02-24T17:07:19.000Z - 4 months ago

Grail rises 14.9%

Feb 23, 2026, 9:06 AM EST - 4 months ago

'Holy Grail' Honus Wagner card sells for over $5M as family auctions it from grandfather's collection

Feb 20, 2026, 4:26 PM EST - 4 months ago

This once-hot cancer-detection company's stock got cut in half after a failed trial

Feb 20, 2026, 8:35 AM EST - 4 months ago

Grail shares plunge after major cancer screening trial misses main goal

Feb 20, 2026, 4:06 AM EST - 4 months ago

Grail Stock Plunges 50% After Earnings. But It's These Test Results That Are to Blame.

Feb 19, 2026, 9:27 PM EST - 4 months ago

Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Feb 19, 2026, 5:00 PM EST - 4 months ago

GRAIL Earnings Call Transcript: Q4 2025

Feb 19, 2026, 5:00 PM EST - 4 months ago

GRAIL Annual report: Q4 2025

Feb 19, 2026, 5:00 PM EST - 4 months ago

GRAIL Earnings release: Q4 2025

Feb 19, 2026, 4:02 PM EST - 4 months ago

GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 19, 2026, 4:01 PM EST - 4 months ago

Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate

Feb 16, 2026, 9:00 AM EST - 4 months ago

GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results

Jan 29, 2026, 7:25 PM EST - 5 months ago

GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

Jan 26, 2026, 8:00 AM EST - 5 months ago

A Study on Aging Unlocks Holy Grail of Sports Performance

Jan 12, 2026, 10:30 AM EST - 6 months ago

GRAIL Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 6 months ago

GRAIL Slides: 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 4:01 PM EST - 7 months ago

GRAIL to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 2, 2025, 3:00 PM EST - 7 months ago

GRAIL Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 9:11 AM EST - 7 months ago

Deutsche Bank may have just set a holy-grail goal for the S&P 500

DB IVV SPXL SPY SSO UPRO VOO

Nov 18, 2025, 4:02 PM EST - 8 months ago

GRAIL to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 10:00 AM EST - 8 months ago

GRAIL Transcript: Wolfe Research Healthcare Conference 2025

Nov 13, 2025, 11:00 AM EST - 8 months ago

GRAIL Transcript: Analyst Day

Nov 12, 2025, 4:30 PM EST - 8 months ago

GRAIL Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 8 months ago

GRAIL Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 8 months ago

GRAIL Earnings release: Q3 2025

Nov 12, 2025, 4:02 PM EST - 8 months ago

GRAIL Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 4:02 PM EST - 8 months ago

GRAIL to Present at 7th Annual Wolfe Research Healthcare Conference

Oct 29, 2025, 4:02 PM EDT - 8 months ago

GRAIL to Announce Third Quarter 2025 Financial Results

Oct 22, 2025, 8:05 PM EDT - 9 months ago

Odds of these speculative stocks making you money seems very slim, says Jim Cramer

ASTS TGEN TMQ AUR RGTI

Oct 20, 2025, 8:00 AM EDT - 9 months ago

GRAIL Transcript: Study Result

Oct 20, 2025, 8:00 AM EDT - 9 months ago

GRAIL Press release: Study Result

Oct 20, 2025, 8:00 AM EDT - 9 months ago

GRAIL Slides: Study Result

Oct 20, 2025, 6:30 AM EDT - 9 months ago

GRAIL, Inc. Announces $325.0 Million Private Placement Financing

Oct 20, 2025, 6:00 AM EDT - 9 months ago

GRAIL and University of Oxford to Present Long-Term Data From the SYMPLIFY Study Evaluating the Galleri® Multi-Cancer Early Detection Test in Symptomatic Individuals at the Early Detection of Cancer Conference (EDCC)

Oct 17, 2025, 6:08 PM EDT - 9 months ago

GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings

BinaryLogic Jun. 23 at 1:03 AM

1 · Reply

bonniewinter Jun. 16 at 5:35 PM

0 · Reply

Bazzzigar Jun. 9 at 5:40 PM

$GRAL moved to MANE

0 · Reply

TheUnmaker Jun. 9 at 11:47 AM

$TNXP $GRAL $CCCC $QSI

0 · Reply

ripster47 Jun. 5 at 3:12 PM

0 · Reply

LewisDaKat Jun. 5 at 10:30 AM

0 · Reply

LewisDaKat Jun. 5 at 10:00 AM

0 · Reply

gobio Jun. 5 at 12:14 AM

0 · Reply

LewisDaKat Jun. 4 at 8:00 PM

$GRAL Why Grail Stock Popped Today https://marketwirenews.com/stock/gral/news/why-grail-stock-popped-today-4936013861703078.html?utm_source=stocktwits

0 · Reply

LewisDaKat Jun. 4 at 7:30 PM

0 · Reply

CapitalMonk Jun. 4 at 3:13 PM

$GRAL Price: $68.09 (+11.39%) Trend: Bearish Market Bias (7D): Bearish Bias 📉 Expected Range: ±4.83% RSI: 57.9 | Momentum: Moderate Volume: -48.0% vs avg Volatility: 4.76% Support: $54.52 | Resistance: $79.50 Data and analytics sourced from Given Analytics educational research: https://www.givenanalytics.com/

0 · Reply

larryr15 Jun. 3 at 6:29 PM

$GRAL I realized lately that most of these experts who have so much hostility towards Galleri are cancer researchers. What do you think will happen to funding for cancer research if cancer mortality rates go way down because many cases are caught much earlier?

0 · Reply

Everestlostfoundmean Jun. 3 at 1:10 AM

$ABVX $GRAL Hall of shame

0 · Reply

MantasTrades Jun. 2 at 6:07 PM

$GRAL 70's Coming, Loading more here

0 · Reply

notreload_ai Jun. 1 at 7:31 PM

At ASCO 2026, $GRAL Galleri multi-cancer blood test showed promise but missed its main goal in the large NHS trial. Experts say it’s not ready for broad population screening yet. https://notreload.xyz/xy/grail-galleri-blood-test-not-ready-for-widespread-use/

0 · Reply

MarcoFla99 Jun. 1 at 1:58 PM

$GRAL Wow, MM's really screwed buyers last week pumping this tio $73. I should have shorted this...damn

0 · Reply

Arcides Jun. 1 at 1:06 PM

$GRAL pupu again, coming to 54?

0 · Reply

SM07 Jun. 1 at 12:50 PM

$GRAL It’s effectively game over.

0 · Reply

oneyedjacks Jun. 1 at 12:33 PM

$GRAL management blew study design. They have 1 year of cash left with current run rate. Damn shame

1 · Reply

SkippyDolittle Jun. 1 at 7:05 AM

$GRAL Stage IV reductions building round over round (9% → 22% → 26%) and PATHFINDER2, the data behind the FDA filing, came in strong. Solid specificity, robust detection, clean safety. The test works, the late-stage signal is real and strengthening, and the worst is already priced.

2 · Reply

MarketBeat Jun. 1 at 1:05 AM

https://marketbeat.com/a/8685450/ $GRAL GRAIL’s Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint

1 · Reply

janed102 May. 30 at 10:06 PM

$GRAL NHS to reject ‘holy grail’ cancer test. The NHS will not adopt a new blood test for cancer, despite trials showing it can diagnose four times as many patients as standard screening, The Telegraph understands. Health chiefs do not believe the test detects cancers early enough, making it ineffective for widespread use

1 · Reply

Market Cap	2.97B
Revenue (ttm)	147.17M
Net Income (ttm)	-408.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-277.47%
Debt to Equity Ratio	0.00

Volume	337,900
Avg Vol	714,766
Day's Range	N/A - N/A
Shares Out	42.92M
Stochastic %K	80%
Beta	3.22
Analysts	Sell
Price Target	$66.00